Address the challenges of cannabidiol (CBD) bioavailability, patient convenience, and compliance
While there is remarkable opportunity for the development of CBD-based pharmaceutical products, progress has been limited by its highly lipophilic and poorly soluble crystalline nature and low bioavailability. In fact, the oral bioavailability of CBD can be as low as 6% in humans, as a result of incomplete absorption in the gut and significant pre-systemic elimination in the liver.1
This has slowed the development of patient-friendly solid oral dosage forms—until now.
CBtru®, an innovative formulated CBD drug product intermediate and patent-pending solution, is making a new era in medicine possible—one that unlocks the true potential of CBD. Its optimized bioavailability in solid oral dosage forms is paving the way for more patient-friendly delivery systems, such as tablets and capsules. Not only will this increase patient convenience and compliance—but also make CBD available to more patients worldwide.
Make oral solid dosage forms a reality in CBD innovation for the first time ever—supporting enhanced patient-centricity and wider applicability.
Harness three to four times higher API loading to achieve lower daily dosages and more convenience for patients.
CBtru® has a comparable bioavailability to the only market-approved CBD drug product, which is a liquid oil-based dosage form.
Clinical research confirms that CBtru® is safe and well-tolerated in humans.
New clinical research validates that our first-of-a-kind CBD drug product intermediate, CBtru®, offers optimized bioavailability in oral solid dosage forms, which is as good as the current gold-standard liquid oil-based CBD medicine. Plus, it may offer a more reliable and consistent uptake, less dependent on food intake.
Discover how we joined forces with Oz Medicann Group (OMG) Pharma–-an Australian-based biotech innovator in the cannabinoid medicines domain—to create a CBD-based oral solid dosage form using CBtru®. Together, we pioneer patient-friendly orally disintegrating tablets (ODTs) for the treatment of insomnia.
1. Perucca and Bialer. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. Cannabinoids in Neurology and Psychiatry, 2020.
2. Millar et al. Towards better delivery of cannabidiol (CBD). Pharmaceuticals (Basel), vol. 13, pg. 219, 2020.
Simplify the drug approvals process with Verilege™, an expert services platform offering regulatory, quality, sustainability, and supply chain support for APIs.
Discover our novel portfolio offering for the pharmaceutical market, which aims to address a growing need for full-service flavor solutions and taste modulation strategies.
New study confirms CBtru®, a novel CBD drug product intermediate, demonstrates equal bioavailability to leading oil-based CBD drug product.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.